arrow
A

Adam Foye

medicine
H指数:23
被引数:4,048

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer

复杂结构变异的趋同进化驱动转移性前列腺癌的疗法抗性

2026-04-150
OAAI
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

2025-07-070
OAAI
Racial variation in the advanced prostate cancer genome

晚期前列腺癌基因组中的种族差异

2025-03-310
OA
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
2024-08-130
OAAI
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer
2024-07-172
OAAI
An atlas of accessible chromatin in advanced prostate cancer
2024-04-050
PRE
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2023-06-0817
OAAI
Genomic and epigenomic drivers of double-negative metastatic prostate cancer
2023-06-020
PRE
Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer
2023-06-020
PRE
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
2022-10-1733
OAAI
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

匹配的患者活检的转录谱阐明了恩杂鲁胺诱导的谱系可塑性的分子决定因素

2022-09-1521
OAAI
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

转录谱分析确定了与恩扎鲁他胺抗性相关的雄激素受体活性低,stemness程序

2020-05-1894
OAAI
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

转移性去势抵抗性前列腺癌预后不良和恩扎鲁他胺耐药的基因组驱动因素

2019-11-01111
OAAI
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
2019-02-2581
OAAI